Skip to Content

Rinvoq Dosage

Generic name: upadacitinib 15mg
Dosage form: tablet, extended release

Medically reviewed by Last updated on Jul 14, 2020.

Dosage in Rheumatoid Arthritis

The recommended oral dose of RINVOQ is 15 mg once daily with or without food [see Clinical Pharmacology (12.3)].

RINVOQ may be used as monotherapy or in combination with methotrexate or other nonbiologic DMARDs.

Important Administration Instructions

  • RINVOQ initiation is not recommended in patients with an absolute lymphocyte count (ALC) less than 500 cells/mm3, absolute neutrophil count (ANC) less than 1000 cells/mm3, or hemoglobin level less than 8 g/dL [see Warnings and Precautions (5.5)].
  • RINVOQ is not recommended for use in patients with severe hepatic impairment (Child-Pugh C) [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)].
  • RINVOQ tablets should be swallowed whole. RINVOQ should not be split, crushed, or chewed.

Dose Interruption

RINVOQ treatment should be interrupted if a patient develops a serious infection until the infection is controlled [see Warnings and Precautions (5.1)].

Interruption of dosing may be needed for management of laboratory abnormalities as described in Table 1.

Table 1: Recommended Dose Interruptions for Laboratory Abnormalities
Laboratory measure Action
Absolute Neutrophil Count (ANC) Treatment should be interrupted if ANC is less than 1000 cells/mm3 and may be restarted once ANC return above this value
Absolute Lymphocyte Count (ALC) Treatment should be interrupted if ALC is less than 500 cells/mm3 and may be restarted once ALC return above this value
Hemoglobin (Hb) Treatment should be interrupted if Hb is less than 8 g/dL and may be restarted once Hb return above this value
Hepatic transaminases Treatment should be interrupted if drug-induced liver injury is suspected

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Frequently Asked Questions